Picture of Avantor logo

AVTR — Avantor News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Avantor raises FY revenue growth, profit guidance after Q3 beat

Avantor raises FY revenue growth, profit guidance after Q3 beat


Overview

  • US life science tools firm's Q3 sales rose 4.6%, beating analyst expectations

  • Adjusted EPS for Q3 beat analyst expectations

  • Company raised FY 2026 guidance for organic revenue growth, adjusted EPS and free cash flow


Outlook

  • Avantor raises FY 2026 organic revenue growth outlook to +0.75% to +1.25% from -0.5% to +0.5%

  • Company lifts FY 2026 adjusted EPS guidance to $0.81-$0.83 from $0.80-$0.83

  • Avantor increases FY 2026 free cash flow forecast to $525 mln-$550 mln from $500 mln-$550 mln


Result Drivers

  • SEGMENT PERFORMANCE - VWR Distribution & Services delivered improved revenue performance with organic growth accelerating to 5.8%, while Bioscience & Medtech Products returned to organic growth as expected

  • EXECUTION IMPROVEMENTS - Co attributed results to sharpened strategic focus and improved execution


Company press release: ID:nPn5mJV9a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$1.70 bln

$1.64 bln (15 Analysts)

Q3 Adjusted EPS

Beat

$0.22

$0.21 (16 Analysts)

Q3 Net Income

$203.40 mln

Q3 Gross Profit

$534.80 mln

Q3 Operating Income

$139.50 mln

Q3 Pretax Profit

$98 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 15 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Avantor, Inc. is $15.00, about 12.4% below its October 27 closing price of $17.13

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view

  • Oct 27 - Repligen Q3 revenue beats estimates on higher demand; lifts outlook

  • Oct 27 - Nautilus Biotechnology Q3 revenue beats


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Avantor

See all news